Widespread Use of GLP‑1 Medications
About three million Canadian adults are currently using GLP‑1 drugs such as Ozempic and Mounjaro, a new survey suggests. These medications, originally developed for diabetes treatment, have gained popularity for weight management. The findings come from a Leger Healthcare poll conducted online with more than 1,500 Canadians aged 18 and over. ([turn0search19][turn0search22])
GLP‑1 drugs work by reducing appetite and food cravings, and many users report significant changes in daily eating behaviour. Weight loss remained the top reason people take these medications, followed by diabetes management and heart health. More Canadians said they would consider taking a GLP‑1 if cost and insurance coverage were more favourable. ([turn0search19][turn0search26])
Eating Habits Are Changing
More than half of survey respondents who take GLP‑1 medications reported reduced appetite. Around 40 per cent said they experienced fewer food cravings, making meal decisions easier. These appetite changes have translated into altered food consumption patterns among many users. ([turn0search19][turn0search22])
About 30 per cent of GLP‑1 users said they now dine out less often or order fewer take‑out meals. Many reported choosing smaller portions or opting for healthier food choices like fruits, vegetables, and lean proteins more frequently. Around 36 per cent also said they had reduced alcohol consumption. These shifts suggest the medications are affecting not only health but everyday lifestyle decisions. ([turn0search19][turn0search20])
Spending Patterns Reflect Lifestyle Shifts
The changing eating patterns are influencing consumer spending habits. Survey data shows that users are reallocating their food budgets, which could affect broader retail patterns in Canada. Some reported spending less on restaurants and snacks, while others are buying more fresh produce and products associated with health and wellness. This evolving behaviour is reshaping household spending priorities. ([turn0search19][turn0search20])
Beyond groceries, GLP‑1 users also said their spending on items such as clothing, personal care, beauty services, and fitness has increased. Experts say this could reflect a broader shift toward spending on well‑being and lifestyle improvements as users adopt new health goals. ([turn0search20][turn0search26])
Barriers and Interest Among Non‑Users
The poll suggests that cost and lack of insurance coverage remain the biggest barriers for Canadians who want to try GLP‑1 drugs. More than half of those not currently taking the medications said they would be more likely to do so if insurance plans offered better coverage or if lower‑cost generic options became available.
An estimated two million adults said they are interested in GLP‑1 medications but have not started them yet. Some cited concerns about potential side effects, including nausea or gastrointestinal discomfort, as factors affecting their decision. ([turn0search19][turn0search26])
Health and Consumer Trends in Focus
The growing use of GLP‑1 medications reflects broader trends in health, wellness and consumer behaviour. As millions of Canadians adjust their diets and spending habits, researchers say these trends may influence food service, retail and health‑care sectors.
This survey highlights how modern medications are linking health outcomes to everyday choices. With interest in GLP‑1 drugs rising, policymakers, insurers and businesses may face new pressures to adapt to changing consumer needs.
